Lipid Nanoparticle– tag –
-
bioRxiv Preprint: Novel ‘Post-Loading’ Strategy for RNA into Empty Lipid Nanoparticles Solves Cold Chain Challenges
bioRxiv USA Overview A bioRxiv preprint introduces a novel 'post-loading' strategy for RNA into lipid nanoparticle (LNP) carriers. This method allows empty LNPs to be manufactured and stored separately, with RNA loaded just prior to admi... -
Imperial College Develops Prostate-Targeted mRNA Nanogels, Overcoming Liver Accumulation in Cancer Therapy
Imperial College London UK Overview Researchers at Imperial College London have developed prostate-targeted degradable polymer nanogels for mRNA delivery in prostate cancer treatment. This innovation overcomes the challenge of tissue-spe... -
Beyond Vaccines: mRNA Technology Expands into Personalized Cancer, Protein Replacement, and Regenerative Medicine
Unknown Global Overview mRNA technology is rapidly expanding beyond vaccines into new medical applications, including personalized cancer vaccines, protein replacement therapies, and regenerative medicine. Ongoing research is actively fo... -
Self-Amplifying RNA (saRNA) Gains Ground Over Conventional mRNA, Proving Superiority Across Diverse Therapeutics; First COVID-19 Vaccines Approved in Japan and EU
TriLink BioTechnologies USA Overview Self-amplifying RNA (saRNA) is gaining traction over conventional mRNA due to its ability to amplify transcripts inside cells, producing more protein per molecule and sustaining expression for days to... -
Penn Engineering Develops LNP-Based ‘One-Two Punch’ to Transform Oral Cancer Treatment: Co-Delivering p53 & Ciclopirox Significantly Reduces Tumor Burden in Resistant Models
Penn Engineering (University of Pennsylvania) USA Overview Researchers at Penn have developed a lipid nanoparticle (LNP) formulation to co-deliver two drugs, p53 and ciclopirox, for oral cancer treatment. This LNP platform aims to simult... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
LNP-Delivered Multi-Specific CAR mRNA Engineering Platform Advances: Enables Controllable In Vivo CAR Expression, Overcomes Autologous Cell Manufacturing Challenges
Ace Therapeutics Unknown Overview A lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapy platform is advancing as a novel strategy to generate CAR-expressing immune cells in vivo. This approach allows for transient and contro... -
LNP-Mediated Gene Therapy to Correct ACTA2 Mutations Shows Promise: Reduces Stroke-Related Mortality, Offers Re-dosability & Lower Costs Over Viral Vectors
MSMDS.org USA Overview A novel lipid nanoparticle (LNP)-based gene therapy strategy is under development to correct ACTA2 mutations in vascular smooth muscle cells. This approach offers significant advantages over viral vectors, includin... -
Complete Guide to Lipid Nanoparticles (LNP): Foundational Technology for Nucleic Acid Delivery Validated by mRNA Vaccine Success
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) are nanoscale delivery vehicles designed to protect and deliver nucleic acids like mRNA and siRNA into cells, serving as the delivery platform for COVID-19 mRNA vaccines. LNPs o... -
Advances in LNP-Mediated Nucleic Acid Delivery to Respiratory & GI Mucosa: AI Integration for Personalized DDS Future
MDPI Switzerland Overview Lipid nanoparticles (LNPs) are rapidly advancing as a versatile platform to overcome delivery barriers for nucleic acids to respiratory and gastrointestinal mucosal sites. LNPs offer tunable physicochemical prop...
